SquareMind announced $18 million in funding, including previously undisclosed pre-Series A financing, to advance its robotic skin imaging platform and expand access to high-quality dermatology exams.
The round was led by Sonder Capital, with participation from Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and a group of individual investors. The funding will support the expansion of SquareMind’s commercial, engineering, and customer support teams ahead of the planned launch of its Swan robotic platform in the United States and Europe.
SquareMind’s flagship product, Swan, is designed as the first robotic system capable of capturing standardized, full-body dermoscopic skin imaging. The platform functions as an augmented dermatoscope, enabling clinicians to examine the entire skin surface with a level of detail typically limited to close-up mole inspections.
The system automates image capture in a matter of minutes and integrates into clinical workflows, helping dermatologists document and monitor skin conditions more efficiently. Swan is paired with AI-driven software that assists in identifying and tracking new or evolving lesions over time, while maintaining physician oversight for diagnosis and treatment decisions.
The company is addressing a growing imbalance between demand and capacity in dermatology. Skin screenings are the most common procedure in the field, yet increasing patient demand, driven in part by aging populations, has led to long wait times and limited opportunities for comprehensive documentation. Early detection remains critical, as the majority of melanoma cases originate from newly developed lesions.
SquareMind’s approach aims to reduce clinician workload, improve diagnostic consistency, and enable scalable access to high-quality skin exams through a combination of robotics and artificial intelligence.
KEY QUOTES:
“We are excited to partner with Sonder Capital and all our investors as we ready ourselves to bring Swan to market and respond to the strong traction we are seeing from practices and hospitals. Dermatologists are operating under increasing pressure, facing strong cognitive load and fatigue. Our technology acts as their companion, helping to reduce this burden, optimize their time, and support comprehensive documentation so they can stay focused on patient care and clinical decision-making.”
Ali Khachlouf, Co-Founder And Chief Executive Officer, SquareMind
“We fundamentally believe that advances in AI and medical robotics will reshape medical practice by automating routine procedures, optimizing clinical time, and expanding access to high-quality care. SquareMind has developed a truly unique platform that has the potential to become the global standard of care in modern dermatology.”
Kate Garrett, Managing Partner, Sonder Capital
